Verona Pharma Plc News - VRNA

Professional-Grade Tools, for Individual Investors.

Premium

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024

PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of...

Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., April 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona...

Form PRE 14A - Other preliminary proxy statements

Form 3 - Initial statement of beneficial ownership of securities

Andrew Fisher Joins Verona Pharma as General Counsel

LONDON and RALEIGH, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

PDUFA Target Action Date for ensifentrine of June 26, 2024 Commercialization preparations advance Strong...

Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

powerwalker 6 days ago

Someone certainly does not want this stock to go and stay above $28.

👍️0

Hoskuld 2 weeks ago

Got it - you meant pharmacies not pharmas (which are drug manufacturing companies.) Makes sense. I will actually check to see if ohtuvayre is at local CVS this week!

I can imagine you would be excited about this and I am really looking forward to hearing about your experience with it! Thanks for sharing!

👍️0

Roger1 2 weeks ago

Btw, I didn't say it wasn't going well. I said it takes time for any new drug given the logistics. I think they're doing a great job or i wouldn't have invested in them.

👍️ 1

Roger1 2 weeks ago

Checked out the drug with CVS and was told about specialty pharmas. I'm a COPD patient and respiratory therapist and have followed trials for quite a while and am delighted to try this drug. Was told the same thing by Verona when I signed up for the drug through the patient portal. I used to teach the mechanism of action of bronchodilators. Specifically C3-5AMP . Taught therapists, nurses, and many of the older physicians sat in for refresher.
Check with your pharmacist and see if it's available. I'd be interested in your findings.

👍️0

Hoskuld 2 weeks ago

They were already detailing 100 of the top 2,500 pulmonologists as of 2 weeks ago, and presumably are detailing ~20-25 more each week. The launch is already going well.

What did you mean by "speciality pharmas until then"?

👍️ 1

Roger1 2 weeks ago

I think it will be January b4 the roll out is complete. Specialty pharmas until then. Have patience, this drug will be a blockbuster with its double mechanism of action.

👍️0

Hoskuld 2 weeks ago

Hi PW - the company has said that they are looking to partner ohtuvayre in the EU and, as a part of that partnership, the partner would be responsible for developing an inhaler for ohtuvayre, too.

I agree that the company management seems sharp. And all newly launched products have issues - let's hope Verona is on top of the issues. I wrote IR and simply asked that they send me a note saying that my message was received and the responsible people at Verona are "on it".

👍️ 1

powerwalker 2 weeks ago

Hoskuld, I listened to the quarterly cc and the Canaccord Genuity presentation and I came away with the impression that Verona management is on top of all matters: marketing, sales, and distribution. If there were a problem, it might be the pharmacies listing Ohtuvayre in their systems, given it is a new product and it needs to establish an ordering pattern for it.

Hoping the patient numbers are higher within a year.

Have you seen or heard any info on EMA and/or UK filings/approval?

👍️ 1

Hoskuld 2 weeks ago

Just following up on this...I can see ohtuvayre being the SOC. I think this will grow very, very swiftly.

🎯 1 👍️ 1

Hoskuld 2 weeks ago

A couple of pulmonologists on stocktwits describe issues with scripts that they have written being fulfilled. On the other hand, one of the pulmonologists is writing 5-6 scripts per day and the other seemed to be writing 2 per day. 5-6 per day = 1,000+ per year for one high-prescribing pulmonologist. And ~400 for a less aggressive prescriber. To me, those seem like promising numbers and point to hitting 60,000+ plus patients over the next year as being probable and NOT a stretch.

🎯 1 👍️ 1

Hoskuld 2 weeks ago

Luckily, we know the story here.

👍️ 1

powerwalker 2 weeks ago

Not actually a "Hit" piece, but leaves negative impressions, anyway. Released earlier in late July ... must not have had the intended effect, so it tries again.

Top 3 Health Care Stocks That May Crash In August

https://www.benzinga.com/news/24/08/40365322/top-3-health-care-stocks-that-may-crash-in-august

👍️0

Hoskuld 2 weeks ago

Glad you are making money here k9uwa! I think we will see this go much higher over the next couple of years. Would really like to get access to script data...

👍️0

k9uwa 2 weeks ago

Hope everyone is buckled in and enjoying the ride. I Am Wishing I had put another zero onto my purchase on this one.
Thanks U and Guzzie
John k9uwa

❤️ 1

Hoskuld 2 weeks ago

Anyone have IMS / IQVIA script data access for Ohtuvayre? Has been a few weeks and this is doing exactly what it should do. Hope everyone is buckled in and enjoying the ride.

👍️ 2

Golden Cross 2 months ago

$VRNA COPD drug approved
- 1st-in-class neb PDE4 inhibitor
- antinflamm + b-dilator
- Clean, broad label, no restrictions
- Complements ICS LABA LAMA, doesn't compete
- Targets broad COPD population vs. narrow biologics like Dupixent
- Big Pharma (Boehringer, GSK) easy bolt-on addition to pipeline

👍️ 1

Golden Cross 2 months ago

$VRNA NEWS FDA Approval ~ Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
$VRNA NEWS FDA Approval ~ Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)https://t.co/6gOmzKSwx2— 💸 Golden Cross Stocks 💸 (@CrossStocks) June 26, 2024

🍀 1 👍️ 1 💎 1 💯 1

HMB2010 2 months ago

In 2021, Nuance Pharma entered into an agreement with Verona Pharma for the exclusive rights to develop and commercialize ensifentrine in Greater China. On April 6th 2023, Nuance Pharma announced first patient in (FPI) for the ENHANCE-China Phase III clinical trial.

https://finance.yahoo.com/news/nuance-pharmas-partner-verona-pharma-090700900.html

Should be good return here!

👍️0

stock1ace1 2 months ago

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine

👍️ 2 💯 1 💲 1 🛫 1

Golden Cross 2 months ago

so is the price already figured in or what here

🍀 1 👍️ 1 💎 1

Golden Cross 2 months ago

$VRNA awaits FDA decision on June 26 for ensifentrine, a groundbreaking COPD therapy. With $901.89M in cash, they’re set for a strong future. Approval could make ensifentrine the first new inhaled #COPD treatment in 20+ years!

🍀 1 👍️ 2 💎 1 💯 1

PonkenPlonken 3 months ago

Today, we have entered into two strategic financing agreements with Oaktree and OMERS, providing access to up to $650M to support the potential US launch of #ensifentrine and the expansion of its clinical activities.
Read more here: https://t.co/vF5GOXjXtN$VRNA pic.twitter.com/pRMLsHPe0t— Verona Pharma (@VeronaPharma) May 9, 2024
this does not look like Ensifentrine is expected to fail.

👍️0

Amatuer17 1 year ago

https://seekingalpha.com/article/4594258-verona-pharma-ensifentrine-vs-dupixent-ensifentrine-is-a-breath-of-fresh-air

Firstly, in the Phase 3 ENHANCE-1 and ENHANCE-2 trials, ensifentrine reported a 36% and 42% pbo-adjusted reduction in COPD exacerbation at week 24, respectively. In contrast, dupixent demonstrated a 30% pbo-adjusted reduction in COPD exacerbation at week 52 in the BOREAS trial.

Verona Pharma is expected to submit an NDA by 1H 2023, PDUFA by 1H 2024, and launch in the US by 2H 2024.

👍️ 1

4Godnwv 2 years ago

Great news today AH - this little pharm might be going places.

👍️0

TheFinalCD 2 years ago

25.77

👍️0

Amatuer17 2 years ago

COPD is a crowded place - not sure about what is special about their drug?

Unless this drug is better than other COPD drugs - this co is fully priced @ $2 B

This co cannot market the product even if approved - so it needs to be bought out but it will not get more than $3 B - so maybe 50% premium from here

👍️0

Laster 2 years ago

Very few sure bets on Nasdaq.
But I think it is a safe bet that this company will be bought out in 2023. Significantly high stock price.
Patience will pay off here.
JMO.

👍️0

TheFinalCD 2 years ago

$23's

👍️0

Zadie420 2 years ago

Which one does not have debt? Really!!!!!!

$5.8 Mil is peanuts compare to other companies. Next time read before you posted.

👍️0

BottomBounce 2 years ago

$VRNA Has $5.83M DEBT

👍️0

TheFinalCD 2 years ago

17.77

👍️0

TheFinalCD 2 years ago

https://finviz.com/quote.ashx?t=VRNA&p=d

👍️0

TheFinalCD 2 years ago

NEWS https://finance.yahoo.com/news/verona-pharma-announces-ensifentrine-meets-070000223.html

👍️0

crudeoil24 2 years ago

Verona Pharma Announces Proposed Underwritten Public Offering Of 10M ADSs
4:42 pm ET August 9, 2022 (Benzinga) Print
Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announced a proposed underwritten public offering of 10 million American Depositary Shares ("ADSs"), each representing eight ordinary shares of Verona Pharma, nominal value £0.05 per share (the "Offering"). All ADSs in the Offering will be offered by Verona Pharma. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering. In addition, Verona Pharma intends to grant the underwriters of the Offering a 30-day option to purchase up to an additional 1.5 million ADSs at the public offering price, less the underwriting discount and commission.

👍️0

tw0122 2 years ago

Big COPD runner today broke 52 week highs premarket

👍️0

georgie18 3 years ago

VRNA...$6.91...Looking for a strong bouncer on the Gap Fill...imo...we shall see...

Chart...https://schrts.co/SknAkrda ...

👍️0

georgie18 3 years ago

VRNA...$7.32...on the Gappa...Psar flipped Bullish yesterday...Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China
$40 million upfront including $25 million cash and $15 million in equity in Nuance Biotech (parent company)
Up to $179 million in potential clinical, regulatory, and commercial milestone payments plus tiered double-digit royalties
Nuance Pharma is responsible for all costs related to development and commercialization of ensifentrine in China...https://www.otcmarkets.com/stock/VRNA/news/story?e&id=1919123 ...Should be a great trader today...imo...we shall see...:partying_face:

👍️0

ClayTrader 4 years ago

* * $VRNA Video Chart 07-17-2020 * *

Link to Video - click here to watch the technical chart video

👍️0

Pyramid2 4 years ago

Congrats to all that Traded this one today!

👍️0

Dubster watching 4 years ago

I’ve move up!
I keep finding these pops

👍️0

FAGIxDILUTIONxDDMASTER 4 years ago

This thing is moving back to $6 and has a huge potential runway, even analysts are saying $34-$50 a share - I always cut their projections in half especially wedbush (who held 70,000 shares as of march 31st).

That still leaves us with a 5x potential over medium to long term - this thing can dance with news buckle up.

👍️0

Clemdane 5 years ago

Something's brewing here

👍️0

PatiencePaysOff79 5 years ago

$VRNA-Someone’s got $150k on the bid at $5.80 a/ha. Something brewing again?

👍️0

Polebarn 5 years ago

This thing at $60 yet?

BAHAHAHAHA....

👍️0

BoilerRoom 5 years ago

Stop the bleed! Company is obviously diluting shares!!!

👍️0

BoilerRoom 5 years ago

Calling $3.80 the bottom here.

👍️0

BoilerRoom 5 years ago

How we doing here today? Green?

👍️0

TheFinalCD 5 years ago

sub $6

SMH

👍️0

BoilerRoom 5 years ago

Ok well good luck buddy

👍️0

PatiencePaysOff79 5 years ago

It’s a big board stock. Company can’t dilute without filing with SEC and notifying shareholders.

👍️0

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Verona Pharma Plc (VRNA)

Professional-Grade Tools, for Individual Investors.

VRNA News

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024

Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update

Form PRE 14A - Other preliminary proxy statements

Form 3 - Initial statement of beneficial ownership of securities

Andrew Fisher Joins Verona Pharma as General Counsel

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

VRNA Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Verona Pharma Plc (VRNA) News

Verona Pharma Plc (VRNA)

Professional-Grade Tools, for Individual Investors.

VRNA News

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024

Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update

Form PRE 14A - Other preliminary proxy statements

Form 3 - Initial statement of beneficial ownership of securities

Andrew Fisher Joins Verona Pharma as General Counsel

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

VRNA Discussion

Your Recent History